AffiliationDepartment of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX, UK. Fiona.Blackhall@christie-tr.nwest.nhs.uk
MetadataShow full item record
AbstractImprovements in conventional cytotoxic treatment have probably reached a plateau for the treatment of lung cancer; therefore, new treatment strategies that are based on a better understanding of tumour biology are required. Some progress has been made for non-small cell lung cancer, in which erlotinib (Tarceva, OSI-774; Genentech), an epidermal growth factor receptor antagonist, has demonstrated a significant clinical benefit in a Phase III randomised trial, and has been licensed for second- or third-line treatment. Other therapies under investigation include angiogenesis inhibitors, COX-2 inhibitors, retinoids, farnesyl transferase inhibitors, Bcl-2 inhibitors and c-Kit antagonists. In this article the recent and ongoing Phase II and III trials of these therapies in lung cancer are summarised, and the prospects for their further clinical development are discussed.
CitationPerspectives on novel therapies for bronchial carcinoma. 2005, 6 (7):1157-67 Expert Opin Pharmacother
JournalExpert Opinion on Pharmacotherapy
- Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.
- Authors: Auberger J, Loeffler-Ragg J, Wurzer W, Hilbe W
- Issue date: 2006 Jun
- Targeted therapies in the treatment of advanced non-small-cell lung cancer: update.
- Authors: Mendoza L
- Issue date: 2009
- [Targeted therapies. New hopes, new challenges].
- Authors: Barlési F
- Issue date: 2008 Jun
- [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
- Authors: Grimm CF, Blum HE, Geissler M
- Issue date: 2005 Jun 10
- Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
- Authors: Langer CJ
- Issue date: 2004 Mar 1